For 30 years, the Clinique médicale l’Actuel, under the medical direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
I-score: Introducing the patient’s perspective in the evaluation of ART
with Dr. Réjean Thomas and Dr. Bertrand Lebouché
- Taking the patient’s perspective into account is an essential step in evaluating retroviral treatments
- The tolerability of patients to treatment is a crucial factor in ensuring adherence
- Using Patient-Reported Outcomes in the field of HIV therapy
- I-score: an evaluation tool for the timely detection of the risks of non-adherence
This activity is supported
by an educational grant from:
Patient’s Perspective in HIV Treatment
In this program, Dr. Bertrand Lebouché discusses the importance of the patient’s perspective in evaluating antiretroviral treatments.
Despite their high virological efficicacy, we still see a number of these treatments failing, mainly due to patients not adhering to their treatment. It is important to take into account the patient’s perception of the treatment, which very often differs from the doctor’s perception. The use of patient-reported outcomes in HIV therapy, along with the eventual development of the I-score, could enable the timely detection of the risks of non-adherence.
Réjean Thomas, MD, Dhc
CEO | Founder
Clinique médicale l’Actuel:
Centre of excellence in
HIV – STIs – Hepatitis
Affiliated with the Centre Hospitalier de l’Université de Montréal (CHUM)
Bertrand Lebouché MD, PhD
Chronic Viral Illness Service
McGill University Health Centre (MUHC)
Montréal, Québec, Canada
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Réjean Thomas, MD, Dhc has a financial interest/relationship or affiliation in the form of:
Advisory: AbbVie, Bristol-Myers Squibb Janssen, Gilead, Merck, ViiV Healthcare
Bertrand Lebouché MD, PhD has a financial interest/relationship or affiliation in the form of:
Industry funded research/investigator, Speakers Bureau, Faculty, Peer Reviewer Advisory Committee/Board : MSD
Speakers Bureau, Faculty, Peer Reviewer Advisory Committee/Board: Gilead, ViiV, BMS, Abbvie
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.